Palatin Technologies
John Dodd, PhD, has 40 years of experience in the discovery and development of clinically relevant drugs. Prior to joining Palatin, Dodd was a director in immunology chemistry at Bristol-Myers Squibb, and before that rose to research fellow at the Robert Wood Johnson Pharmaceutical Research Institute (J&J).
This person is not in the org chart
This person is not in any offices
Palatin Technologies
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system.